IMR Press / EJGO / Volume 34 / Issue 1 / pii/1630905362659-1029904146

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases
Show Less
1 Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama
2 Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama
3 Department of Obstetrics and Gynecology, Tokyo University School of Medicine, Bunkyo-ku, Tokyo
4 Department of Obstetrics and Gynecology, National Hospital Organization Nishi-Saitama Chuo Hospital, Tokorozawa, Saitama
5 Department of Obstetrics and Gynecology, Nara Prefectural, Nara Hospital, Nara (Japan)
Eur. J. Gynaecol. Oncol. 2013, 34(1), 90–93;
Published: 10 February 2013
Abstract

Background: A combination therapy with gemcitabine and oxaliplatin (GEMOX) yielded a moderate activity in platinum-resistant ovarian cancers; however, frequent severe toxicities, such as thrombocytopenia and neurotoxicity, were observed. A certain modification of schedule might therefore facilitate the clinical application of the regimen. The authors report two cases thatachieved complete response to a weekly administration of bevacizumab and GEMOX. Materials and Methods: Two patients with platinum-resistant recurrent ovarian cancers received a weekly regimen of GEMOX with bevacizumab: 2 mg/kg of bevacizumab, 300 mg/m2 of gemcitabine, and 30 mg/m2 of oxaliplatin, three weeks on and one week off, Q4 weeks. Complete remission wasobserved after three to four courses of therapy. Hematologic and non-hematologic toxicities more than grade 2 were not observed during chemotherapy. The patients are now without tumor progression more than 12 months after initiation of therapy. Conclusion: Weekly administration of bevacizumab and GEMOX had potential activity in recurrent and refractory ovarian carcinomas. These findings warrant necessity of further trial in such clinical settings.
Keywords
Ovarian cancer
Recurrence
Weekly therapy
Bevacizumab
Gemcitabine/oxaliplatin
Share
Back to top